Indian generic drugmakers, such as Dr Reddy's, Cipla, and Sun Pharma, maintain revenue growth in FY25 due to US drug shortages.

Indian drugmakers, such as Dr Reddy's, Cipla, and Sun Pharma, which have the US market as a key segment, will sustain their revenue growth in FY25 due to drug shortages in the US. Mumbai-based India Ratings and Research noted that the world's largest drug market is facing decade-high drug shortages, with an active shortage of 233 drugs across 22 therapeutic categories. US-catering Indian generic players have experienced strong financial performance during FY24 due to these shortages.

May 27, 2024
6 Articles